Compare Crispr Therapeutics AG (CRSP) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs TeraWulf Inc — how do they compare? Crispr Therapeutics AG trades at $50.45 (market cap $4.97B), while TeraWulf Inc trades at $19.09 (market cap $9.61B). The key difference: TeraWulf Inc is the larger of the two by market cap, and TeraWulf Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | WULF | |
|---|---|---|
Market Cap | $4.97B | $9.61B |
Sector | Health | Technology |
52-Week High | $76.78 | $28.98 |
52-Week Low | $44.34 | $4.76 |
Enterprise Value | $3.32B | $12.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
WULF trades at $20.89, down 4.92% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $661.42 million in 2025, with revenue of $168.46 million, but secured a significant 20-year, $19 billion AI infrastructure deal with Anthropic, driving positive analyst sentiment. Key support lies at $20, with resistance at $21.
The outlook hinges on execution of the Anthropic partnership, offering substantial growth potential, but high valuation ratios and persistent losses pose risks. Analyst consensus is strongly bullish with a $35.40 price target, though operational cash flow remains negative. Investors face volatility from execution delays and competitive pressures in AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
